Aktis Oncology

Founded 2020 · CIK 0002035832 · Biotech · Public

Miniprotein radioconjugates targeting tumor antigens for cancer therapy

aktisoncology.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$175M
1 Form D · Oct 2024
24 months since last filing
Contracts
—
No federal contracts on record
Patents
27
2 granted · 25 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$175,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1936CELLARCUS TECHNOLOGIES, LLC——
1937DeepSpace Storage Systems Inc.—$1.3M
1938Centrexion Therapeutics Corp—$189M
1939Aktis Oncology—$175M
1940Quotient Ltd—$92M
1941Myota, Inc.—$16M
1942AXIOMX INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Todd FoleyDirector
  • Ken HerrmannDirector
  • Helen KimDirector
  • Andrew LevinDirector
  • Oleg NodelmanDirector
  • Matthew RodenDirector · Executive Officer
  • Shulamit Ron-BiggerExecutive Officer
  • Lloyd SegalDirector

Patents

USPTO · 2 granted of 27
  • B7-H3 Miniproteins, Conjugates, And Uses Thereofgranted
  • Miniproteins, Conjugates & Uses Thereofapplication
  • B7-H3 Miniproteins, Conjugates, And Uses Thereofapplication
  • NECTIN-4 Miniprotein Conjugatesapplication
  • Nectin-4 binding miniproteins, conjugates and methods of use thereofgranted
  • B7H3 Miniprotein Conjugatesapplication
  • B7H3 Miniprotein Conjugatesapplication
  • B7H3 Miniprotein Conjugatesapplication
  • Decoy Miniproteins, Compositions, & Methods Of Useapplication
  • NECTIN-4 Miniprotein Conjugatesapplication
  • B7H3 Miniprotein Conjugatesapplication
  • NECTIN-4 Miniprotein Conjugatesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.